Rousselot leads on innovation at CPhI with state-of-the-art gelatins

Published: 28-Aug-2018

Rousselot, leading global producer of gelatin and collagen peptides, focuses on highlighting its unrivalled portfolio of premium gelatins for advanced pharma and biomedical applications at this year’s CPhI Worldwide

At bioLIVE stand 12B13, Rousselot will present its medical grade gelatin range, X-Pure, with outstanding levels of purity for in-body applications.

Rousselot will be running a number of expert-led talks throughout the show, where attendees can expand their knowledge on the effects of endotoxin.

From its nutraceutical product portfolio, Rousselot will present its recently launched Peptan IIm, a hydrolysed collagen type II matrix that specifically targets joint health at a lunch brief and partnering sessions in a dedicated meeting space.

Rousselot X-Pure for regenerative medicine applications: a unique and global range of purified gelatins

At its booth at the CPhI’s bioLIVE area, Rousselot will introduce its low-endotoxin X-Pure range for the first time to the European market.

Advanced gelatins with low endotoxin levels are needed for demanding medical applications including haemostatic medical devices, parenteral formulations and regenerative medicine applications.

With endotoxin levels below 100, 20 or 10 Endotoxin Units per gram (EU/g) or even below LAL analysis detection limits, the X-Pure range offers unrivalled levels of safety for all these in-body medical applications.

For regenerative medicine, in particular, Rousselot has developed five X-Pure gelatins to exactly match the needs of diverse final medical applications.

These five gelatin grades come with different viscosities, gel strengths and endotoxin levels and bring significant technical advantages for cell growth or cell transportation, tissue engineering or 3D printing for example.

To find out more about Rousselot’s wide range of innovative ingredients visit stand 12B13 at CPhI.

Relevant companies

You may also like